Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sun Pharma Advanced Research Co's enterprise value is ₹74,640 Mil.
Sun Pharma Advanced Research Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹15,974 Mil. Therefore, Sun Pharma Advanced Research Co's EV-to-EBITDA for today is 4.67.
The historical rank and industry rank for Sun Pharma Advanced Research Co's EV-to-EBITDA or its related term are showing as below:
NSE:SPARC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -140.75 Med: -30.25 Max: 5.72
Current: 4.67
During the past 13 years, the highest EV-to-EBITDA of Sun Pharma Advanced Research Co was 5.72. The lowest was -140.75. And the median was -30.25.
NSE:SPARC's EV-to-EBITDA is ranked better than 87.42% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.37
vs NSE:SPARC: 4.67
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sun Pharma Advanced Research Co (NSE:SPARC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sun Pharma Advanced Research Co's PE Ratio (TTM) for today is calculated as:
Sun Pharma Advanced Research Co's share price for today is ₹213.21.
Sun Pharma Advanced Research Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹47.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharma Advanced Research Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sun Pharma Advanced Research Co's EV-to-EBITDA falls into.
Sun Pharma Advanced Research Co's current Enterprise Value is ₹74,640 Mil.
Sun Pharma Advanced Research Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹15,974 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co (NSE:SPARC) has a EV-to-EBITDA of 4.67 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sun Pharma Advanced Research Co. According to the industry distribution chart, Sun Pharma Advanced Research Co ranks #93 out of 739 companies in the Drug Manufacturers industry, placing it in the top 12.6%.
Is Sun Pharma Advanced Research Co's EV-to-EBITDA too high?
Sun Pharma Advanced Research Co's current EV-to-EBITDA is 4.67. The Drug Manufacturers industry median EV-to-EBITDA is 13.37. Sun Pharma Advanced Research Co's value of 4.67 is 65.1% below this industry median. Based on the distribution chart, Sun Pharma Advanced Research Co ranks #93 out of 739 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sun Pharma Advanced Research Co ranks #93 out of 739 companies for EV-to-EBITDA. This places Sun Pharma Advanced Research Co in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.37. Sun Pharma Advanced Research Co's value of 4.67 is 65.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.37, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharma Advanced Research Co's current EV-to-EBITDA of 4.67 is 65.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sun Pharma Advanced Research Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharma Advanced Research Co's current EV-to-EBITDA is 4.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹82.92, compared to a current price of ₹213.21 — trading 157.1% above its estimated fair value. The current EV-to-EBITDA is 4.67 and 65.1% below the Drug Manufacturers industry median of 13.37. Sun Pharma Advanced Research Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current EV-to-EBITDA is 4.67 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be overvalued.
The current stock price of ₹213.21 is trading 157.1% above its estimated GF Value™ of ₹82.92.
GuruFocus considers Sun Pharma Advanced Research Co to be Significantly Overvalued.
Key valuation signals for NSE:SPARC:
EV-to-EBITDA: 4.67
GF Value™: ₹82.92 vs. price of ₹213.21 (157.1% above fair value)
Industry Position: 65.1% below the Drug Manufacturers median (#93 of 739)
No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
44GF Score
Get the complete analysis for NSE:SPARC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SPARC has been successfully added to your 
